Search hospitals > Maine > Scarborough
Maine Center for Cancer Medicine-Scarborough
Claim this profileScarborough, Maine 04074
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
98 reported clinical trials
1 medical researcher
Summary
Maine Center for Cancer Medicine-Scarborough is a medical facility located in Scarborough, Maine. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Lung Cancer, Prostate Cancer and other specialties. Maine Center for Cancer Medicine-Scarborough is involved with conducting 98 clinical trials across 102 conditions. There are 1 research doctors associated with this hospital, such as Chiara Battelli, MD.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
HER2 negative
2Non-Small Cell Lung Cancer
Global LeaderStage I
Stage II
Stage III
Top PIs
Clinical Trials running at Maine Center for Cancer Medicine-Scarborough
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
ALK Gene Rearrangement
Skin Cancer
Cutaneous Melanoma
Melanoma
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Maine Center for Cancer Medicine-Scarborough?
Maine Center for Cancer Medicine-Scarborough is a medical facility located in Scarborough, Maine. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Lung Cancer, Prostate Cancer and other specialties. Maine Center for Cancer Medicine-Scarborough is involved with conducting 98 clinical trials across 102 conditions. There are 1 research doctors associated with this hospital, such as Chiara Battelli, MD.